Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties

James A. McCubrey; Akshaya K. Meher; Shaw M. Akula; Stephen L. Abrams; Linda S. Steelman; Michelle M. LaHair; Richard A. Franklin; Alberto M. Martelli; Stefano Ratti; Lucio Cocco; Fulvio Barbaro; Przemys&#x142;aw Duda; Agnieszka Gizak

doi:doi:10.18632/aging.204038

← Back

Research Paper Volume 14, Issue 8 pp 3365—3386

Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties

Figure 2. Effects of signal transduction inhibitors on the growth of MIA-PaCa-2 + WT-TP53 and MIA-PaCa-2 + pLXSN cells. The effects of docetaxel (A), etoposide (B) aclacinomycin (C) and daunorubicin (D) on MIA-PaCa-2 + pLXSN cells (solid red squares) and MIA-PaCa-2 + WT-TP53 cells (solid blue circles) were examined by MTT analysis. These experiments were repeated and similar results were obtained. Statistical analyses were performed by the Student T test on the means and standard deviations of various treatment groups. ^***P < 0.0001.